It was great to attend Formulation & Delivery Europe 2026 in Basel last month – a valuable opportunity to explore the latest industry trends in drug formulation and delivery, connect with industry experts to build collaborations, and discuss the technologies shaping the future of healthcare. Innovation is moving quickly in combination products and alternative routes …

We do not believe many other London based start-ups have their own labs to be able to manufacture products, but here at Calla Lily Clinical Care, we have done exactly that. All of our Callavid® design validation and clinical trial products started their production here in London. Now that our clinical trial is underway, our …

What a way to close out Day 2 of ESHRE 2026! 🌅 We were delighted to co-host an European Society of Human Reproduction and Embryology (ESHRE) Sundowner with our brilliant partners Hertility and Impli… held on the rooftop of the Lillet Bar overlooking the Thames and the iconic London skyline. 🚠 The energy was electric …

Super excited to chair the Women’s Health Horizons DC summit on October 7 and be a panelist on “Medical Education as Health Policy: If We Don’t Teach It, We Don’t Treat It.” Everything policy and women’s health. It’s a real milestone in my life. The realization that everyone would prefer it if what I have …

It’s been an intense but very productive 42nd European Society of Human Reproduction and Embryology (ESHRE) Congress – the world’s largest gathering of professionals in reproductive medicine and embryology, held at Excel London. 🌸 So many great conversations, catch-ups and new connections forged: all united by a shared mission to improve fertility outcomes in the …

FREEDOM trial reaches 100% patient consent. Calla Lily Clinical Care is pleased to share an important milestone in our NIHR funded FREEDOM clinical trial. In less than three months since recruitment began, FREEDOM has passed its safety stopping rule, and all target patient participants are now consented. More than half of total participants have also …

We’re delighted to be featured by Technology Networks in this interview with our co-founders, Dr Lara Zibners and Thang Vo-Ta, about our Callavid® intravaginal drug delivery platform. Our first focus is progesterone delivery for threatened miscarriage and IVF– areas where the clinical need is significant, but where the patient experience has too often been overlooked. …

With our FREEDOM clinical trial making exciting progress– now 60% recruited — we are delighted to start receiving national media coverage for this important step towards a more patient-centric option for women suffering from threatened miscarriage. A big thank you to the Daily Mail for featuring Callavid® and our University Hospitals Coventry and Warwickshire (UHCW) …

Our colleagues Ewa Radziwon and Shaun Knights had a very productive few days at INDEX Nonwovens INDEX™26 in #Geneva, hosted by EDANA, the voice of nonwovens 🇨🇭 As the world’s leading nonwovens exhibition, it was important for Calla Lily Clinical Care to attend again: reconnecting with existing suppliers, meeting potential new partners, and exploring exciting …

It was recently World Clinical Trials Day, and our co-founder Lara took part in a special event hosted by SökerData and Covington & Burling LLP: 🔬 “Innovation in Action: Successful Women’s Clinical Trial Case Studies” 🧪 Lara shared the context, design and exciting early progress of our ongoing FREEDOM clinical trial evaluating Callavid® for threatened …